Ceramide-antiestrogen nanoliposomal combinations-novel impact of hormonal therapy in hormone-insensitive breast cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2352-2361

  Morad, Samy A F ^a,d   Levin, Jonathan C ^a   Shanmugavelandy, Sriram S ^b   Kester, Mark ^b   Fabrias, Gemma ^c   Bedia, Carmen ^c   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^d South Valley University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CERAMIDASE; CERAMIDE; ESTROGEN RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; SPHINGOSINE 1 PHOSPHATE; TAMOXIFEN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL ASSAY; CELL DEATH; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG FORMULATION; ENZYME ACTIVITY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME MEMBRANE; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

AMIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASPASES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CERAMIDES; ESTROGEN RECEPTOR MODULATORS; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; LIPOSOMES; LYSOSOMES; MITOCHONDRIA; MODELS, BIOLOGICAL; NANOPARTICLES; TAMOXIFEN;

EID: 84869225019     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0594     Document Type: Article

References (50)

1. Liu YY, Han TY, Giuliano AE, Ichikawa S, Hirabayashi Y, Cabot MC. Glycosylation ofceramidepotentiates cellular resistance to tumornecrosis factor-alpha-induced apoptosis. Exp Cell Res 1999;252:464-70. (Pubitemid 29530276)
2. Bleicher RJ, Cabot MC. Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 2002;1585:172-8. (Pubitemid 36092082)
3. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999;274:1140-6.
4. Meng A, Luberto C, Meier P, Bai A, Yang X, Hannun YA, et al. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp Cell Res 2004;292:385-92. (Pubitemid 38018853)
5. Gomez-Munoz A, Gangoiti P, Granado MH, Arana L, Ouro A. Cer-amide- 1-phosphate in cell survival and inflammatory signaling. Adv Exp Med Biol 2010;688:118-30.
6. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011;36:97-107.
7. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10:489-503.
8. Oskouian B, Saba JD. Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol 2010;688:185-205.
9. Graf C, Klumpp M, Habig M, Rovina P, Billich A, Baumruker T, et al. Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol Pharmacol 2008;74:925-32.
10. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism- a strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93:347- 57.
11. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008;9:662-73.
12. Beckham TH, Elojeimy S, Cheng JC, Turner LS, Hoffman SR, Norris JS, et al. Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets 2010;14:529-39.
13. Canals D, Perry DM, Jenkins RW, Hannun YA. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 2011;163:694-712.
14. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J 2010;12:171-80.
15. Stover T, Kester M. Liposomal delivery enhances short-chain cer-amide- induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 2003;307:468-75. (Pubitemid 37310658)
16. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008;14:3571- 81.
17. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, et al. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo . Drug Metab Dispos 2008;36:1709-15.
18. Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro . Biochim Biophys Acta 2003;1612:98-106. (Pubitemid 36555692)
19. Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, et al. Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J Surg Res 1996;66:31-5. (Pubitemid 27009372)
20. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997;272:1682-7. (Pubitemid 27043253)
21. Guo R, Huang Z, Shu Y, Jin S, Ge H. Tamoxifen inhibits proliferation and induces apoptosis in human hepatocellular carcinoma cell line HepG2 via down-regulation of survivin expression. Biomed Pharmacother 2009;63:375-9.
22. Jiang Y, Divittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, et al. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biol Ther 2011;12:574- 85.
23. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, Kimchi ET, et al. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 2011;60:695-701.
24. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010;116:4192-201.
25. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006;1:1458- 61.
26. Bedia C, Casas J, Garcia V, Levade T, Fabrias G. Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases. Chembiochem 2007;8:642-8. (Pubitemid 47194856)
27. Kirkegaard T, Roth AG, Petersen NH, Mahalka AK, Olsen OD, Moilanen I, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010;463:549-53.
28. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008;27:6434- 51.
29. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005;11:3465 - 74.
30. Colombini M. Ceramide channels and their role in mitochondria-mediated apoptosis. Biochim Biophys Acta 2010;1797:1239-44.
31. Morales A, Lee H, Goni FM, Kolesnick R, Fernandez-Checa JC. Sphingolipids and cell death. Apoptosis 2007;12:923-39. (Pubitemid 46653290)
32. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, et al. New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 2006;580:4751-6. (Pubitemid 44189397)
33. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004;309:523-32. (Pubitemid 38542603)
34. Chapman JV, Gouaze-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, et al. Metabolism of short-chain ceramide by human cancer cells-implications for therapeutic approaches. Biochem Pharmacol 2010;80:308-15.
35. Lee JY, Bielawska AE, Obeid LM. Regulation of cyclin-dependent kinase 2 activity by ceramide. Exp Cell Res 2000;261:303-11. (Pubitemid 32010227)
36. Phillips DC, Hunt JT, Moneypenny CG, Maclean KH, McKenzie PP, Harris LC, et al. Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression. Cell Death Differ 2007;14:1780-91. (Pubitemid 47423645)
37. Ichikawa A, Ando J, Suda K. G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. Hum Cell 2008;21:28-37. (Pubitemid 351499181)
38. Mandlekar S, Hebbar V, Christov K, Kong AN. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 2000;60:6601-6.
39. Callaghan R, Higgins CF. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 1995;71:294-9.
40. Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta 2000;1486:128-44. (Pubitemid 30336797)
41. Chapman JV, Gouaze-Andersson V, Cabot MC. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity. Int J Oncol 2010;37:1591-7.
42. Richter C, Ghafourifar P. Ceramide induces cytochrome c release from isolated mitochondria. Biochem Soc Symp 1999;66:27 -31.
43. Yu T, Li J, Sun H. C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro. Cancer Chemother Pharmacol 2010;66:999-1003.
44. Rizvi F, Heimann T, Herrnreiter A, O'Brien WJ. Mitochondrial dysfunction links ceramide activated HRK expression and cell death. PLoS ONE 2011;6:e18137.
45. Johansson AC, Appelqvist H, Nilsson C, Kagedal K, Roberg K, Ollinger K. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 2010;15:527-40.
46. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, et al. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 2009;13:1449-58.
47. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, et al. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci 2008;13:2293-8. (Pubitemid 351589254)
48. Flowers M, Fabrias G, Delgado A, Casas J, Abad JL, Cabot MC. C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat 2012;133:447-58.
49. Gouaze-Andersson V, Flowers M, Karimi R, Fabrias G, Delgado A, Casas J, et al. Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate 2011;71:1064-73.
50. Hwang JJ, Kim HN, Kim J, Cho DH, Kim MJ, Kim YS, et al. Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals 2010;23:997-1013.